Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine Among Older and Frail Patients With Advanced Gastroesophageal Cancer
The authors of this multicenter, noninferiority, phase III trial evaluated the safety and efficacy of oxaliplatin and capecitabine in elderly frail patients with advanced gastroesophageal cancer. Oxaliplatin and capecitabine were dosed at level A, level B (80% of level A), or level C (60% of level A) in the chemotherapy-intensive arm, or patients were treated with best supportive care. The progression-free survivals associated with both levels B and C were noninferior to level A. Dose level C was associated with the best overall treatment utility. In the group in which chemotherapy was compared with best supportive care, the overall survival was numerically longer for chemotherapy, but this was not statistically significant.